Treatment of Idiopathic Gastroparesis With Injection of Botulinum Toxin Into the Pyloric Sphincter Muscle

Larry S. Miller, M.D., Gregory A. Szych, M.D., Steven B. Kantor, B.A., Matthew Q. Bromer, M.D., Linda C. Knight, Ph.D., Alan H. Maurer, M.D., Robert S. Fisher, M.D., and Henry P. Parkman, M.D.

Sections of Gastroenterology and Nuclear Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania

OBJECTIVES: We aimed to determine if botulinum toxin injection into the pyloric sphincter improves gastric emptying and reduces symptoms in patients with idiopathic gastroparesis.

METHODS: Patients with idiopathic gastroparesis not responding to prokinetic therapy underwent botulinum toxin (80–100 U, 20 U/ml) injection into the pyloric sphincter. Gastric emptying scintigraphy was performed before and 4 wk after treatment. Total symptom scores were obtained from the sum of eight upper GI symptoms graded on a scale from 0 (none) to 4 (extreme).

RESULTS: Ten patients were entered into the study. The mean percentage of solid gastric retention at 4 h improved from 27 ± 6% (normal < 10%) before botulinum toxin injection into the pylorus to 14 ± 4% (p = 0.038) 4 wk after treatment. The symptom score decreased from 15.3 ± 1.7 at baseline to 9.0 ± 1.9 (p = 0.006) at 4 wk, a 38 ± 9% decrease. Improvement in symptoms tended to correlate with improved gastric emptying of solids (r = 0.565, p = 0.086).

CONCLUSIONS: This initial pilot study suggests that botulinum toxin injection into the pylorus in patients with idiopathic gastroparesis improves both gastric emptying and symptoms. (Am J Gastroenterol 2002;97:1653–1660. © 2002 by Am. Coll. of Gastroenterology)

INTRODUCTION

Gastric emptying is a highly regulated process reflecting the integration of propulsive forces generated by proximal fundic tone and distal antral contractions with the resistance of the pyloric sphincter. Antral hypomotility is thought to be a major factor in gastroparesis (1, 2). Current treatment for gastroparesis employs prokinetic agents that increase antral contractility and accelerate gastric emptying (3). Unfortunately, many patients remain symptomatic despite prokinetic agents. In addition, prokinetic agents may produce side effects that limit or prevent their use. Increased gastric outlet resistance due to pyloric dysfunction or pylorospasm has been described in gastroparesis, primarily the diabetic kind (4, 5). Only a few studies have been performed to see whether inhibition of the pyloric sphincter muscle accelerates gastric emptying (6–8). An orally administered smooth muscle relaxant acting systematically might decrease antral contractility, perhaps further delaying emptying (9). Thus, therapy directed to the pylorus alone might be effective and avoid systemic effects.

Botulinum toxin is an inhibitor of cholinergic neuromuscular transmission and has been used to treat spastic disorders of both striated and smooth muscles by local injection into affected muscles (10). Reports by several centers have demonstrated that injection of botulinum toxin directly into the lower esophageal sphincter (LES) in patients with achalasia reduces LES pressure and improves dysphagia (11–14). It may be possible to treat gastroparesis by decreasing pyloric resistance using botulinum toxin injected into the pyloric sphincter muscle. This has previously been suggested to accelerate gastric emptying in diabetic gastroparesis (7, 8). The aim of this study was to determine whether injection of botulinum toxin into the pylorus improves gastric emptying and reduces symptoms in idiopathic gastroparesis.

MATERIALS AND METHODS

Study Subjects

Patients with symptomatic idiopathic gastroparesis not responding to prokinetic therapy were offered enrollment in this open-label pilot trial of botulinum toxin injection into the pyloric sphincter. The study was approved by the Institutional Review Board of Temple University Health Center. These patients had known idiopathic gastroparesis, documented by prior gastric emptying scintigraphy and upper endoscopy, with symptoms of nausea, vomiting, and/or early satiety refractory to prokinetic agents. Patients were excluded if they 1) had a mechanical cause for delayed gastric emptying such as an active pyloric channel ulcer or gastric cancer, 2) had diabetes mellitus (type 1 or 2), 3) had a known coagulopathy, or 4) were pregnant or breast feeding.
**Study Protocol**

Patients were maintained on their prokinetic regimen, if any, before and after botulinum toxin injection. Patients completed a questionnaire grading eight different symptoms including postprandial fullness, early satiety, bloating, epigastric discomfort (an ache or discomfort after eating, poorly localized), epigastric pain (a sharp, easy to pinpoint pain after eating), postprandial nausea, belching after meals, and vomiting on a 5-point scale graded from 0 (none) to 4 (extreme). Total duration and the frequency of the symptoms were also recorded. This symptom questionnaire is similar to one used and validated to evaluate dyspeptic symptoms and the response to prokinetic treatment in patients with gastroparesis (15). A total symptom score was calculated as the sum of each of the eight individual symptom scores, with a maximum total being 32 (16). Symptom scores were obtained before treatment, at 2 and 4 wk after treatment, and then at monthly intervals for 5 months.

Patients then underwent combined solid-liquid gastric emptying scintigraphy. After an overnight fast, the patient consumed the test meal, consisting of an egg sandwich and 300 ml of water. This is the conventional test meal used for clinical evaluation at Temple University Hospital (16, 17). The scrambled eggs were labeled with 500 μCi of technetium Tc-99m sulfur colloid to measure gastric emptying of solids, and the water was mixed with 125 μCi of indium 111 pertechnetate acid to measure gastric emptying of liquids. Scintigraphic images were obtained at 0, 15, 30, 45, 60, 90, 120, 180, and 240 min after meal ingestion. Analysis of the gastric emptying data was performed as previously described (17). Regions of interest were drawn around the stomach for all images acquired. The geometric mean of the gastric counts was determined as the square root of the product of anterior and posterior counts at each imaging time. After correction for radionuclide decay, geometric mean gastric counts at each imaging time were expressed as a percentage of the maximal geometric mean counts at time zero. The percent retention at 2 and 4 h after meal ingestion for solids and 1 and 2 h for liquids were determined. Normal solid phase gastric emptying with this meal is ≤50% retention at 2 h and ≤10% at 4 h for Tc-labeled solids; normal liquid phase gastric emptying is ≤50% retention at 1 h and ≤10% retention at 2 h for In-labeled liquids (17).

If the gastric emptying was delayed, patients then underwent upper endoscopy with examination of the esophagus, stomach, and duodenum. If no structural abnormalities that could cause delayed gastric emptying were present, 1 ml containing 20 U of botulinum toxin type A (Botox, Allergan, Irvine, CA) was injected with a sclerotherapy needle into each of four quadrants of the pyloric sphincter under direct visualization. This total of 80 U of Botox is the same amount injected into the LES for achalasia (11–13). In many of the patients in this study, a fifth 1 ml (20 U) was used, raising the total amount of Botox injected to 100 U in 5 ml (13).

Patients were assessed for symptoms in follow-up at 2 and 4 wk after treatment, and observed thereafter at monthly intervals for 5 months. Follow-up consisted of scoring the same symptoms during the initial assessment. At the 4-wk visit, gastric emptying scintigraphy was repeated.

**Data Analysis and Statistics**

Data collected included the gastric retention of solids and liquids and the symptom scores. The symptom scores and gastric emptying scintigraphy results were compared before and 1 month after botulinum toxin injection in the same patients. Statistical analyses were performed using the paired Student's t test. The change in gastric emptying time activity curves was analyzed with two-way analysis of variance for repeated measures for the two factors, subject and time. The Pearson correlation coefficient was used to correlate the improvement in gastric emptying with the improvement in symptoms. Results are expressed as means ± SEMs.

**RESULTS**

Ten patients with idiopathic gastroparesis entered the study. The patient characteristics are shown in Table 1. All patients were female, with an average age of 41 ± 5 yr (range = 19–70). The duration of gastroparesis averaged 4 ± 1 yr (range = 1–11).

**Gastric Emptying**

An example of the solid phase gastric emptying scintigraphy in an individual patient before and 4 wk after botulinum toxin injection into the pyloric sphincter is shown in Figure 1. Overall, for all 10 patients, the mean values for the gastric emptying time activity curves for solid and liquid phases before and 4 wk after botulinum toxin injection into the pylorus are shown in Figure 2. There was an improvement in gastric emptying of solids after botulinum toxin treatment, as indicated by the gastric retention for solids after botulinum toxin injection being significantly less than the gastric retention before injection (Fig. 2A). Before botulinum toxin injection into the pylorus, the mean percentage of solid retention at 4 h for the 10 patients was 27 ± 6% (normal < 10%). Four weeks after injection, this decreased to 14 ± 4% (p = 0.038). The change in solid phase gastric emptying of the individual patients is shown in Figure 3A. Using the retention of solids at 4 h to assess gastric emptying, seven of the 10 patients had an improvement in gastric emptying at 4 wk after botulinum toxin injection, two patients had no change, and one patient had worsening of gastric emptying.

There was no significant improvement in gastric emptying of liquids after botulinum toxin treatment, as indicated by the gastric retention for liquids after botulinum toxin injection not differing significantly from the gastric retention before injection (Fig. 2B). The mean percentage of liquid retention at 2 h for the 10 patients before botulinum toxin injection was 27 ± 3% (Fig. 3B). Four weeks after
Table 1. Study Patient Characteristics

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age/ Gender</th>
<th>Medical/Surgical Conditions</th>
<th>Main Symptoms</th>
<th>Duration of Symptoms</th>
<th>Prior Treatments</th>
<th>Current Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>70/F</td>
<td>Laparoscopic Toupet for GERD</td>
<td>Nausea, early satiety, bloating, heartburn</td>
<td>4 yr</td>
<td>Metoclopramide, domperidone</td>
<td>Domperidone</td>
</tr>
<tr>
<td>2</td>
<td>43/F</td>
<td>Celiac disease, endometriosis</td>
<td>Abdominal pain, nausea, bloating</td>
<td>1.5 yr</td>
<td>Metoclopramide, cisapride, domperidone</td>
<td>None</td>
</tr>
<tr>
<td>3</td>
<td>40/F</td>
<td>Hypothyroidism, cholecystectomy</td>
<td>Nausea, abdominal pain</td>
<td>2 yr</td>
<td>Cisapride, erythromycin</td>
<td>Metoclopramide</td>
</tr>
<tr>
<td>4</td>
<td>23/F</td>
<td>GERD</td>
<td>Bloating, early satiety, heartburn</td>
<td>4 yr</td>
<td>Metoclopramide, cisapride</td>
<td>Metoclopramide</td>
</tr>
<tr>
<td>5</td>
<td>30/F</td>
<td>Endometriosis, GERD</td>
<td>Bloating, abdominal pain, heartburn</td>
<td>2 yr</td>
<td>Metoclopramide, domperidone</td>
<td>Domperidone</td>
</tr>
<tr>
<td>6</td>
<td>38/F</td>
<td>Hypothyroidism</td>
<td>Nausea, bloating, abdominal pain</td>
<td>10 yr</td>
<td>Metoclopramide, cisapride, erythromycin</td>
<td>Metoclopramide</td>
</tr>
<tr>
<td>7</td>
<td>68/F</td>
<td>Multiple sclerosis</td>
<td>Bloating, abdominal fullness</td>
<td>3 yr</td>
<td>Cisapride</td>
<td>None</td>
</tr>
<tr>
<td>8</td>
<td>33/F</td>
<td>Fibromyalgia, cholecystectomy</td>
<td>Nausea, bloating, early satiety, heartburn</td>
<td>3 yr</td>
<td>Metoclopramide</td>
<td>Metoclopramide</td>
</tr>
<tr>
<td>9</td>
<td>19/F</td>
<td>None</td>
<td>Nausea, fullness, bloating</td>
<td>1 yr</td>
<td>Metoclopramide, domperidone</td>
<td>Domperidone</td>
</tr>
<tr>
<td>10</td>
<td>44/F</td>
<td>GERD</td>
<td>Bloating, nausea, abdominal discomfort</td>
<td>11 yr</td>
<td>Metoclopramide, cisapride, domperidone</td>
<td>None</td>
</tr>
</tbody>
</table>

injection, it was 23 ± 4% (p = 0.217; i.e., no significant change).

Symptoms
The total symptom score decreased from 15.3 ± 1.7 at baseline to 10.3 ± 1.9 (p = 0.034) and 9.0 ± 1.9 (p = 0.006) at 2 and 4 wk, respectively (Fig. 4). These represent 26 ± 14% (p = 0.007) and 38 ± 9% (p = 0.002) improvements of symptoms at 2 and 4 wk, respectively. Overall, nine of the 10 patients had improvement in the total symptom score. There was improvement in the following specific symptoms: postprandial abdominal fullness (in eight patients), bloating (seven patients), early satiety (five patients), epigastric discomfort (five patients), epigastric pain (four patients), and postprandial nausea (four patients). As seen in Table 2, of the eight symptoms scored there were significant decreases in the symptom scores for postprandial fullness (p = 0.009), bloating (p = 0.017), and abdominal discomfort (p = 0.042) and a trend for nausea to be improved (p = 0.068).

Relationship of Improvement in Gastric Emptying to Improvement in Symptoms
The improvement in symptom scores 4 wk after botulinum toxin injection tended to correlate with the improvement in solid phase gastric emptying (at 2 h, r = 0.580, p = 0.080; at 4 h, r = 0.565, p = 0.086) but not at all with the change in liquid gastric emptying (at 2 h, r = 0.112, p = 0.759).

Figure 1. Example of improvement in solid phase gastric emptying after botulinum toxin injection into the pyloric sphincter in a single patient. Shown are the anterior images for the Tc-99m sulfur colloid solid phase marker at 0, 60, 120, and 240 min after meal ingestion. There was less gastric retention after botulinum toxin injection into the pylorus (64% retention at 2 h and 25% retention at 4 h) than at baseline before treatment (86% retention at 2 h and 49% at 4 h).
Figure 2. Gastric emptying time activity curves for solid (A) and liquid (B) phases at baseline before injection and 4 wk after botulinum toxin injection into the pylorus. Shown are the mean ± SEM values for the 10 patients studied. (A) The gastric emptying time activity curve for solids showed significantly less gastric retention after botulinum toxin injection than before injection (two-way analysis of variance: $F = 3.292, p = 0.013$). The gastric retention was significantly less ($p < 0.05$) at 180 and 240 min after meal ingestion. (B) The gastric emptying time activity curve for liquids after botulinum toxin injection did not significantly differ from that before injection (two-way analysis of variance: $F = 0.440, p = 0.818$).

Symptom scores were reduced 46 ± 11% in the seven patients who had improvement in gastric emptying of solids. By comparison, the three patients with no change or worsening of gastric emptying experienced only a 22 ± 11% improvement in symptom scores ($p = 0.219$).

**Long-term Follow-up**

After the assessment 1 month after botulinum toxin injection, patients were observed clinically by their gastroenterologists, who treated the patients symptomatically as needed. All 10 patients have been observed for more than 6 months (Table 3). Three of the 10 patients remain on prokinetic agents, whereas two are on no treatment. Five of the 10 patients have received a repeat botulinum toxin injection into the pylorus. The five patients who had repeat injections had an improvement in symptoms after the first injection, with return of their symptoms after 3–8 months. Each patient also had an improvement in symptoms in response to the second injection, a response lasting 2–6 months. Four of the five patients rated the response to the second injection the same as the first; one patient rated the second injection not as good as the first.

**DISCUSSION**

This open label study demonstrates that botulinum toxin injection into the pyloric sphincter muscle in patients with idiopathic gastroparesis improves gastric emptying and associated symptoms. The improvement in symptoms was moderate, averaging a 38% decrease in overall symptoms, with most patients still having some residual dyspeptic symptoms after treatment.

Botulinum toxin injection into the pylorus improved gastric emptying of solids. Using the percent retention of technetium-labeled solid food at 4 h after meal ingestion for the assessment of gastric emptying, seven of the 10 patients (70%) had improvement in gastric emptying after botulinum toxin injection. We and others have shown (17–19) that extending the radionuclide gastric emptying test to 4 h better separates patients with gastroparesis from those with normal gastric emptying. Interestingly, gastric emptying of liquids did not improve after botulinum toxin injection into the pyloric sphincter. The pylorus acts as a sieve to prevent larger particles from passing into the duodenum; it does not necessarily prevent liquid emptying, which is regulated by the gastroduodenal pressure gradient rather than pyloric resistance (20).

This study showed a reduction in dyspeptic symptoms after botulinum toxin injection into the pylorus. Furthermore, this improvement in symptoms tended to correlate with improvement in gastric emptying of solids. Interestingly, although gastric emptying improved with the treatment, it did not normalize in most patients despite an improvement in symptoms. In prior studies, there has been poor correlation between symptoms and delayed gastric emptying and between symptom improvement and accelerated gastric emptying with prokinetic treatment (21, 22). Stanghellini et al. (23) suggested that the correlation can be improved by evaluating not only the presence of symptoms but also the severity of symptoms. In the present study, both the presence of symptoms and their severity were included in the symptom scores. There were significant decreases in the symptom scores for postprandial fullness, bloating, and abdominal discomfort, and a trend for nausea to be improved.
Figure 3. Effects of botulinum toxin injection into the pylorus on gastric emptying for each patient. (A) Solid phase gastric emptying. Shown is the percentage of retention of Tc-labeled solids at 4 h after meal ingestion. Seven of the 10 patients had an improvement in gastric emptying at 4 wk after botulinum toxin injection, two patients had no change, and one patient had worsening of gastric emptying. Before botulinum toxin injection into the pylorus, the mean percentage of solid retention at 4 h for the 10 patients was 27% (normal < 10%). Four weeks after injection, this decreased to 14%. (B) Liquid phase gastric emptying. Shown is the percentage of retention of In-labeled liquids at 2 h after meal ingestion. There was no significant effect of botulinum toxin injection on liquid phase gastric emptying. The mean percentage of liquid retention at 2 h for the 10 patients before botulinum toxin injection was 27%. Four weeks after injection, it was 23%. The bars represent the mean values of the 10 patients.
This study included only patients with idiopathic gastroparesis. Several other investigators have used botulinum toxin injection into the pylorus for treatment of insulin-dependent diabetic patients with gastroparesis. Lacy et al. (8) injected a larger dose (200 U) of botulinum toxin, with favorable although variable results. Ezzeddine et al. (24) reported that improvements in both gastric emptying and symptoms were observed when 100 U of botulinum toxin were injected into the pylorus in type 2 diabetic patients with gastroparesis. Sharma et al. (7) reported a favorable response in a case report using injection of 80 U of botulinum toxin into the pylorus. Several small studies have reported successful use of botulinum toxin injection into the pylorus for refractory postvagotomy pyloric spasm (two patients, 80 U) (25) and gas-bloat syndrome and dyspepsia after Nissen fundoplication (four patients, 100–200 U) (26).

Studies with botulinum toxin injection into the LES for achalasia have shown that the improvement in symptoms is temporary; in general, symptoms are improved for approximately 3 months (13, 14). Although side effects are rare, reports have been published suggesting that, in some patients, botulinum toxin injection may cause a tissue inflammatory reaction and may make subsequent Heller myotomy, if needed, more difficult. In addition, treatment with botulinum toxin into the LES may lead to heartburn and gastro-esophageal reflux disease. In this study of botulinum toxin injection into the pylorus, patients were observed carefully for the initial month after treatment and for an additional 6 months after injection by telephone interview. A gradual return of symptoms to the baseline condition was observed. Patients generally required further treatment of their gastroparesis, such as cisapride on a compassionate basis or repeat injection of botulinum toxin into the pylorus. So far, no study patient has undergone implantation of a gastric elec-

![Figure 4. Improvement in symptoms after botulinum toxin injection into the pyloric sphincter. Shown are the total symptom scores for each patient before and at 2 wk and 4 wk after botulinum toxin treatment. Overall, nine of the 10 patients had improvement in symptoms. The mean total symptom score decreased from 15.3 at baseline to 10.3 and 9.0 at 2 and 4 wk, respectively. The bars represent the mean values of the 10 patients.](image)

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Before</th>
<th>4 Weeks After BTI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postprandial fullness</td>
<td>2.8 ± 0.2</td>
<td>1.6 ± 0.3</td>
<td>0.009</td>
</tr>
<tr>
<td>Postprandial bloating</td>
<td>2.6 ± 0.2</td>
<td>1.5 ± 0.3</td>
<td>0.017</td>
</tr>
<tr>
<td>Postprandial abdominal discomfort</td>
<td>2.1 ± 0.5</td>
<td>1.1 ± 0.4</td>
<td>0.042</td>
</tr>
<tr>
<td>Early satiety</td>
<td>1.9 ± 0.4</td>
<td>1.5 ± 0.2</td>
<td>0.104</td>
</tr>
<tr>
<td>Postprandial epigastric pain</td>
<td>1.7 ± 0.5</td>
<td>1.0 ± 0.4</td>
<td>0.111</td>
</tr>
<tr>
<td>Postprandial nausea</td>
<td>2.2 ± 0.5</td>
<td>1.3 ± 0.4</td>
<td>0.068</td>
</tr>
<tr>
<td>Belching after meals</td>
<td>1.3 ± 0.3</td>
<td>0.8 ± 0.3</td>
<td>0.177</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0.8 ± 0.4</td>
<td>0.6 ± 0.4</td>
<td>0.168</td>
</tr>
<tr>
<td>Total symptom score</td>
<td>15.3 ± 1.7</td>
<td>9.1 ± 1.0</td>
<td>0.006</td>
</tr>
</tbody>
</table>

Symptoms were graded by the 10 patients on a 5-point scale graded from 0 (none) to 4 (extreme). Results expressed as means ± SEMs.
<table>
<thead>
<tr>
<th>Patient</th>
<th>Amount of Boxtx Injected</th>
<th>Short Term (4 wk)</th>
<th>Long Term (6 mo)</th>
<th>Subsequent Therapy after Initial BTI</th>
<th>Duration of Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>80 U</td>
<td>Improvement</td>
<td>Improvement</td>
<td>Repeat BTI into pylorus at 9 mo after initial BTI</td>
<td>14 mo</td>
</tr>
<tr>
<td>2</td>
<td>100 U</td>
<td>Improvement</td>
<td>No change</td>
<td>Repeat BTI into pylorus at 8 mo after initial BTI</td>
<td>11 mo</td>
</tr>
<tr>
<td>3</td>
<td>80 U</td>
<td>Improvement</td>
<td>Improvement</td>
<td>Repeat BTI into pylorus at 4.5 mo after initial BTI</td>
<td>7 mo</td>
</tr>
<tr>
<td>4</td>
<td>100 U</td>
<td>Improvement</td>
<td>Improvement</td>
<td>Continues on metoclopramide</td>
<td>12 mo</td>
</tr>
<tr>
<td>5</td>
<td>100 U</td>
<td>Improvement</td>
<td>Improvement</td>
<td>Remains on domperidone</td>
<td>7 mo</td>
</tr>
<tr>
<td>6</td>
<td>80 U</td>
<td>Improvement</td>
<td>Improvement</td>
<td>Repeat BTI into pylorus at 11 mo after initial BTI</td>
<td>13 mo</td>
</tr>
<tr>
<td>7</td>
<td>80 U</td>
<td>No change</td>
<td>No change</td>
<td>No therapy for gastroparesis</td>
<td>7 mo</td>
</tr>
<tr>
<td>8</td>
<td>80 U</td>
<td>Improvement</td>
<td>No change</td>
<td>No therapy for gastroparesis</td>
<td>6 mo</td>
</tr>
<tr>
<td>9</td>
<td>100 U</td>
<td>Slight improvement</td>
<td>NA</td>
<td>Started cisapride compassionate use at 2 mo</td>
<td>8 mo</td>
</tr>
<tr>
<td>10</td>
<td>100 U</td>
<td>Improvement</td>
<td>NA</td>
<td>Repeat BTI into pylorus at 5 mo after initial BTI</td>
<td>8 mo</td>
</tr>
</tbody>
</table>

The table shows the patient outcome after Botulinum Toxin Injection (BTI) into the pylorus. Patients received BTI and their short-term and long-term responses were recorded. The subsequent therapy and duration of follow-up are also indicated.

The study evaluated the potential of BTI for gastroparesis. However, it is not clear how long-term control can be achieved with a single injection.

This study was an initial pilot study. Questions remain about the clinical use of botulinum toxin injection for the treatment of gastroparesis. First, the role of relaxing the pylorus in accelerating gastric emptying needs to be further studied. Gastric emptying involves a series of coordinated events including fundic relaxation and contraction, antral contraction, pyloric relaxation, and duodenal contraction. Antral contractility correlates with gastric emptying of solids (28). Recent physiological studies have shown the importance of the pylorus in regulating gastric emptying (5). Although some studies have suggested that pyloromyotomy may not affect gastric emptying (29), other studies have shown it to be beneficial in patients with diabetic gastroparesis (6) and in preventing gastric stasis after a vagotomy (20). Second, the dose of botulinum toxin used in this study (80–100 U) may be too low to fully relax the pylorus. The dose of botulinum toxin chosen was based on previous studies in achalasia (11–13). Lacy et al. (8) injected higher total doses (200 U) of botulinum toxin into the pylorus, with variable results. Third, gastric dumping symptoms have been reported after surgical pyloromyotomy due to the decreased pyloric resistance to large particles of solid food (20). This did not occur in this study after botulinum toxin injection into the pylorus. Fourth, botulinum toxin injection into the pylorus could diffuse into the antrum and decrease antral contractility. This could potentially further delay gastric emptying and worsen the patient’s symptoms. In our study, only one patient had worsening of delayed gastric emptying after botulinum toxin injection. Future studies using endoscopic ultrasound guidance for injection into the pylorus might prevent this theoretical adverse event; endoscopic ultrasound guidance has been used for injecting botulinum toxin into the LES in achalasia (30). Finally, patients with idiopathic gastroparesis likely represent a heterogeneous group with different pathophysiological abnormalities; some groups may respond to botulinum toxin injection and others may not.

Because this was an open label pilot study, there is a potential for study bias. The symptomatic improvement of the patients in this open label study may represent a placebo response. Subsequent studies should evaluate botulinum toxin injection into the pylorus for gastroparesis using a randomized, controlled, double blind design comparing botulinum toxin to placebo (saline sham) injections, similar to the protocol previously employed by Pasricha et al. to study achalasia (12).

In conclusion, botulinum toxin injection into the pyloric sphincter muscle in patients with idiopathic gastroparesis accelerated gastric emptying and reduced dyspeptic symptoms of gastroparesis. This study suggests that the majority of patients with idiopathic gastroparesis will have a modest but significant short-term improvement in gastric emptying and symptoms after botulinum toxin injection into the pylorus.

**ACKNOWLEDGMENT**

This study was supported in part by a National Institutes of Health (NIH) Midcareer Investigator Award in Patient-Oriented Research to H.P.P. (NIH K24 DK02921) and by the NIH General Clinical Research Centers Program of the National Center for Research Resources (RR00349). Study medication was provided by Allergan, Inc.

Reprint requests and correspondence: Henry P. Parkman, M.D., Gastroenterology Section, Parkinson Pavilion, 8th Floor, Temple University Hospital, 3401 North Broad Street, Philadelphia, PA 19140.

Received Nov. 6, 2001; accepted Mar. 21, 2002.

**REFERENCES**


